Clinical study on the clinical efficacy and immune function of anticancer prescription combined with chemotherapy in patients with bladder cancer
- Conditions
- Bladder cancer
- Registration Number
- ITMCTR1900002444
- Lead Sponsor
- Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- Not specified
1 In line with transurethral resection of bladder tumor (TURPBT), and pathological diagnosis of malignant tumors;
2 The Karnofsky Performance Status (KPS) score is >60 points, and the expected survival period is >1 year;
3 Aged 25 to 80 years;
4 Syndrome differentiation belongs to the syndrome type of qi and blood deficiency and phlegm poisoning internal knot in traditional Chinese medicine;
5 Those who have voluntarily signed an informed consent form.
1 Allergic constitution and those who are allergic to experimental drugs;
2 Patients with renal cancer, bladder tuberculosis, and urinary calculi;
3 Combined with other malignant tumor patients;
4 Patients with blood system diseases, coagulopathy and autoimmune diseases;
5 Combined with severe cardiovascular disease, cerebrovascular disease, hematopoietic system disease, neuropathic patients;
6 Participated in other clinical researchers 3 months before the trial;
For the above 6 exclusion criteria, as long as one of the criteria is met, the exclusion criteria are met and need to be excluded.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Bladder cancer syndrome score;Tumor patient Karnofsky Performance Status;
- Secondary Outcome Measures
Name Time Method TCM syndrome score;